Targeting angiogenesis in lung cancer

  • Sameh Daher
  • Jair Bar
short review


Angiogenesis inhibition is a promising way to inhibit and eradicate cancer. Many attempts have been made to use this tool for the treatment of lung cancer. Some success has been reported, and antiangiogenic drugs are actively being investigated in combination with other types of anticancer treatments.


Antiangiogenic drugs Bevacizumab Dual-pathway inhibition 


Conflict of interest

S. Daher and J. Bar declare that they have no competing interests.


  1. 1.
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542.CrossRefPubMedGoogle Scholar
  4. 4.
    Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21:1804.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24:20.CrossRefPubMedGoogle Scholar
  6. 6.
    Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015;10:134.CrossRefPubMedGoogle Scholar
  7. 7.
    Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:4349.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31:3004.CrossRefPubMedGoogle Scholar
  9. 9.
    Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014;25:1044.CrossRefPubMedGoogle Scholar
  10. 10.
    Cortot AB, Audigier-Valette C, Molinier O, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second or third line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): results from the phase III study IFCT-1103 ULTIMATE. J Clin Oncol. 2016;34(Suppl):9005.Google Scholar
  11. 11.
    Jaafar B, De Castro J, Dingemans A‑MC, et al. Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab treatment beyond progression in patients with advanced non-small cell lung cancer (NSCLC) progressing after first-line bevacizumab and chemotherapy. J Clin Oncol. 2017;35:9004.Google Scholar
  12. 12.
    Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre,double-blind, randomised phase 3 trial. Lancet. 2014;384:665–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double blind, randomised controlled trial. Lancet Oncol. 2014;15:143–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Nasser HH, Kaiser R, Sullivan RN, et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol. 2015;31(Suppl):8034.Google Scholar
  15. 15.
    Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012;30:3640.CrossRefPubMedGoogle Scholar
  16. 16.
    Bar J, Shiran I, Urban D, et al. Anti-angiogenic treatments in advanced NSCLC: back to the drawing board. J Thorac Dis. 2012;4(6):643–6.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236.CrossRefPubMedGoogle Scholar
  18. 18.
    Yongzhao Zhao, Huixian Wang, Shi Y, et al. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials. Oncotarget. 2017;8:7014–24.PubMedGoogle Scholar
  19. 19.
    Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer. 2002;86:558.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010;28:43.CrossRefPubMedGoogle Scholar
  21. 21.
    Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29:2215.CrossRefPubMedGoogle Scholar
  22. 22.
    Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009;27:6006.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011;29:4436.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tiseo M, Boni L, Ambrosio F, et al. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;20;35(12):1281–7.CrossRefGoogle Scholar
  25. 25.
    Pujol JL, Lavole A, Quoix E, et al. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Ann Oncol. 2015;26:908.CrossRefPubMedGoogle Scholar
  26. 26.
    Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007;25:4278.CrossRefPubMedGoogle Scholar
  27. 27.
    Ready NE, Pang HH, Gu L, et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin Oncol. 2015;33:1660.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010;5:1835.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010;5:1279.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.CrossRefPubMedGoogle Scholar
  31. 31.
    Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology. 2005;4(Suppl. 3):7–16.Google Scholar
  32. 32.
    Van der Veldt AA, Lubberink M, Bahce I, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012;21(1):82–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat. 2009;12:74–80.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Conley SJ, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA. 2012;109:2784–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Xian X, Håkansson J, Ståhlberg A, et al. Pericytes limit tumor cell metastasis. J Clin Invest. 2006;116(3):642–51.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Döme B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol. 2007;170(1):1–15.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Torok S, Rezeli M, Kelemen O, et al. Limited tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors. Theranostics. 2017;7(2):400–12.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of OncologyChaim Sheba Medical CenterTel HashomerIsrael

Personalised recommendations